Why the study?
Do CYP2C9 and CYP2C19 genetic polymorphisms influence warfarin maintenance dose and metabolic clearance in outpatients on long-term therapy?
Do CYP2C9 and CYP2C19 genetic polymorphisms influence warfarin maintenance dose and metabolic clearance in outpatients on long-term therapy?
CYP2C9 genetic polymorphisms significantly influence warfarin dose requirements and S-warfarin metabolic clearance, highlighting the potential role of pharmacogenetics in guiding warfarin dosing.
No takes yet. Share an insight, caveat, or question.
CYP2C9 genotyping should not yet guide warfarin dosing; leaves open prospective validation of pharmacogenetic algorithms.
M.G. Scordo (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: